2019
DOI: 10.3892/etm.2019.7763
|View full text |Cite
|
Sign up to set email alerts
|

Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non‑obese type 2 diabetic Goto‑Kakizaki rats

Abstract: Diabetic cardiomyopathy, especially myocardial ischemia reperfusion (I/R) injury, is a major cause of morbidity and mortality in type 2 diabetic patients. The increasing of basal p38 MAP Kinase (p38 MAPK) activation is a major factor that aggravates cardiac death on diabetic cardiomyopathy. In addition, metformin also shows cardio-protective effects on myocardial ischemia/reperfusion injury. In this study, we investigated the effect of the combination between metformin and p38 MAPK inhibitor (SB203580) in diab… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 12 publications
(9 citation statements)
references
References 43 publications
(47 reference statements)
0
9
0
Order By: Relevance
“…The role of p38 in the control of intracellular Ca 2+ was corroborated in H9c2 cells: phosphodiesterase-inhibitor–mediated reduction in ERK1/2, JNK, and p38 activation reduced ischemia-induced apoptosis and restored normal calcium influx, oxidative stress levels, and eNOS expression [ 81 ]. p38 inhibition also potentiates the metformin-induced reduction in myocardial ischemia–reperfusion injury in non-obese type 2 diabetic rats [ 82 ].…”
Section: P38 In Ischemia–reperfusion Injurymentioning
confidence: 99%
“…The role of p38 in the control of intracellular Ca 2+ was corroborated in H9c2 cells: phosphodiesterase-inhibitor–mediated reduction in ERK1/2, JNK, and p38 activation reduced ischemia-induced apoptosis and restored normal calcium influx, oxidative stress levels, and eNOS expression [ 81 ]. p38 inhibition also potentiates the metformin-induced reduction in myocardial ischemia–reperfusion injury in non-obese type 2 diabetic rats [ 82 ].…”
Section: P38 In Ischemia–reperfusion Injurymentioning
confidence: 99%
“…Met is also used in the treatment of diabetes complications such as DCM. Metformin ameliorates metabolic disorders, reduces ROS production and cardiac cell death, and improves myocardial structure and function on DCM (Sanit et al, 2019;Yang et al, 2019). Met also protects against brain and liver injury by activating AKT phosphorylation (Naicker et al, 2016;Xu et al, 2016).…”
Section: Introductionmentioning
confidence: 99%
“…24 In non-obese type 2 diabetic Goto-Kakizaki rats, metformin or SB203580 can significantly reduce the size of myocardial infarction, and the combination of metformin and SB203580 can enhance the cardioprotection. 25…”
Section: Discussionmentioning
confidence: 99%